

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: August 18, 2016

Chairperson: Stephen Richards, D.O.

Time: 9:33 a.m. to 11:34 a.m.

Location: Capitol Room 116, Des Moines, Iowa

Committee Members Present: Stephen Richards, D.O.; Mark Graber, M.D.; Carole Frier, D.O.; Bruce Alexander, Pharm.D.; Jolene Kelly, PA-C; Holly Randleman, Pharm.D.; and Heidi Price-Eastman, R.Ph.

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant

Iowa Medicaid Enterprise (IME) Staff Present: Steve Liles, Pharm.D.; Lauren Biczak, D.O.; Erin Halverson, R.Ph.; Gina Tiernan, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Sandy Pranger, Amerigroup Iowa; Jennifer Schonhorst, AmeriHealth Caritas Iowa, and Karrie Hansotia, United Healthcare Plan of the River Valley.

Chairperson Stephen Richards called the meeting to order.

- I. Stephen Richards asked that each committee, DHS, IME, and MCO staff member introduce themselves to the public. The April 21, 2016, open session minutes were reviewed. Bruce Alexander made the motion to approve the minutes, and Mark Graber seconded. The motion passed with no objections.
- II. PDL and Drug Rebate Issues (Dr. Liles): The SSDC pool offers for 2017 will be reviewed by the P&T Committee in November when the entire PDL is reviewed.
- III. PA Criteria/Pro-DUR Edits/Legislation (Dr. Parker): Informational Letters 1664-MC and 1683-MC listed changes to the Preferred Drug List (PDL), new ProDUR quantity limits, and changes to the prior authorization (PA) criteria for: PCSK9 Inhibitors; Entresto; Non-Parenteral Vasopressin Derivatives of Posterior Pituitary Hormone Products; Xyrem; Biologicals for Hidradenitis Suppurativa; Viberzi; Corlanor; Xifaxan; Long Acting Opioids; and Deferasirox. Informational Letter 1676 provided clarification on nonprescription drugs for use by members in NFs, ICF/IDs, and PMIC facilities. Informational Letter 1680-MC notified providers of a Quitline fax number change on the Fee-for-Service Nicotine Replacement Therapy and Smoking Cessation Therapy-Oral PA forms. Informational Letter 1705-MC detailed the dispensing fee change to \$10.02 effective August 1, 2016, pending CMS approval, and Informational Letter 1706-MC provided 2016-2017 Respiratory Syncytial Virus (RSV) information. The committee also received copies of a recommendation letter from the DUR Commission suggesting that methadone be made non-preferred, and the letters sent to the Department of Human Services from the DUR Commission after their June and August meetings, which included recommended criteria for: Long-Acting Opioids; Biologicals for Hidradenitis Suppurativa; Xifaxan; Corlanor;

Deferasirox; Viberzi; Topical Acne and Rosacea Products; Novel Oral Anticoagulants; Potassium Binders; and Nucala.

IV. IME Updates: Committee members were asked to complete their annual conflict of interest and confidentiality forms if they had not already done so.

V. Public Comment: The public speakers were:

Name	Representing	Drug/Topic
Tami Sova	UCB	Briviact
Nikki Moon	Abbvie	Venclexta
Sally Berry	TRIS Pharma	Dyanavel XR Oral Suspension
Paul Amato	ViiV Healthcare	Triumeq
Paul Miner	Gilead	Odefsey
Megan Flynn	Actelion	Opsumit, Uptravi

At 10:11, motion to go to closed session was made by Bruce Alexander and seconded by Jolene Kelly. The motion passed with unanimous approval. Open session resumed at 10:51.

VI. PDL Discussion and Deliberation (Dr. Biczak): All subsequent recommendations were made to maximize cost savings to the program unless otherwise noted. Recommended changes are as follows: Emend to preferred with conditions; verapamil extended release capsules to non-preferred; potassium chloride oral liquid to non-preferred; Monurol to non-preferred; and methadone to non-preferred with conditions based on the recommendation from the Iowa Medicaid Drug Utilization Review (DUR) Commission. All diagnoses will still require prior authorization, but a check box to note usage for opioid dependence will be added to the prior authorization form. Carole Frier motioned to accept the recommendations above, and Bruce Alexander seconded. The decision was unanimous.

VII. RDL Discussion and Deliberation (Dr. Biczak): To maximize cost savings to the program, the following changes were recommended: Novoeight from non-recommended to recommended; Ziagen tablets to non-preferred and abacavir to preferred; and Epivir to non-preferred and lamivudine to preferred. Jolene Kelly motioned to accept these recommendations, and Holly Randleman seconded. All members were in favor. After a clinical review of these drugs related to toxicity and efficacy information, the following were all recommended to change from recommended to non-recommended: Trizivir, Fuzeon, Lexiva, Crixivan, Invirase, Aptivus, Rescriptor, nevirapine, Viramune Oral Suspension, Viramune XR, didanosine, and Videx. Bruce Alexander motioned to accept these changes, and Carole Frier and Holly Randleman seconded simultaneously. The decision was unanimous.

VIII. Newly Released Drugs (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. Dr. Biczak reviewed the new drugs, and then the committee voted unanimously in favor of all the recommendations. Heidi Price-Eastman made the motion, seconded by Jolene Kelly, to accept the following changes: Briviact to non-preferred; Cabometyx to non-recommended with conditions; Descovy to preferred; Odefsey to non-preferred; and Uptravi to non-preferred with conditions. Holly Randleman made the motion,

seconded by Mark Graber, to accept the following changes: Varubi to non-preferred with conditions; Venclexta to non-recommended with conditions; Viberzi to non-preferred with conditions; Vraylar to non-preferred step 3; and Zepatier to preferred with conditions.

- IX. Newly Released Generic Drugs (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. The following will all be non-preferred: darifenacin er, miglitol, mometasone nasal, naftifine, and rosuvastatin. These drugs will all be non-preferred with conditions: alogliptin, alogliptin-metformin, alogliptin-pioglitazone, flurandrenolide, and frovatriptan. Bruce Alexander motioned to accept the above recommendations. Jolene Kelly and Holly Randleman seconded simultaneously, and all members were in favor.
- X. New Drug Dosage Forms/Strengths/Combinations (Dr. Biczak): All of the following recommendations were made to maximize cost savings to the program unless otherwise noted. Here is a breakdown of the PDL or RDL statuses for these new drugs: Adzenys XR ODT and Quillichew ER, preferred with conditions; Durlaza and Fyavolv, non-preferred; Narcan Nasal Spray, preferred; Kovaltry, non-recommended; and the remaining four, Dyanavel XR, Envarsus XR, Sernivo, and Xeljanz XR, all non-preferred with conditions. Bruce Alexander made the motion to accept the above recommendations. Carole Frier seconded the motion, and all members were in favor.
- XI. Review of Draft P&T Antiretroviral Document (Erin Halverson): At the April meeting, the committee asked that a letter be drafted regarding HIV treatments and dosing benefits (single tablet and extended release regimens being preferred over those requiring multiple tablets or doses) and costs, per the discussion based on public comments (regarding adherence related to single tablet regimens) and the associated costs in closed session. They reviewed the drafted document, and did not have any additional changes or suggestions. Per unanimous committee vote (motion by Holly Randleman, second by Mark Graber), this letter will now be finalized with P&T letterhead and forwarded on to the Department of Human Services. Members will be provided a copy of the finalized version via email.
- XII. FluMist (Dr. Biczak): Dr. Biczak presented information on FluMist, as it was recently discussed by the Advisory Committee on Immunization Practices (ACIP). It is recommended to be not covered on the PDL unless new information is released, as use of the live attenuated vaccine is no longer advised by the ACIP.

A motion was made by Mark Graber to adjourn the meeting. Carole Frier seconded, all in attendance approved. The meeting adjourned at 11:34 a.m. The next scheduled meeting is tentatively set for November 17, 2016.